Investment
Features
FeesSafety
Academy
More
Pluang+

Compare CVS Health Corp (CVS) vs Deutsche Bank AG (DB) Price & Performance

CVS Health CorpTrade
Deutsche Bank AGTrade

Price performance (Past 24H)

Key statistics

CVS Health Corp vs Deutsche Bank AG — how do they compare? CVS Health Corp trades at $87.04 (market cap $112.29B), while Deutsche Bank AG trades at $33.68 (market cap $62.42B). The key difference: CVS Health Corp is the larger of the two by market cap, and Deutsche Bank AG pays the higher dividend (3.46%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Deutsche Bank AG for 80 Days on average.

CVSDB
Market Cap
$112.29B$62.42B
Volume
7,763,6762,918,760
Sector
HealthFinancials
52-Week High
$110.60$41.56
52-Week Low
$70.08$28.37
Typical Hold Time
83 Days80 Days
Enterprise Value
$174.64B$77.06B
Dividend Yield
3.03%3.46%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

CVS Health Corp

CVS Health trades at $87.12, down 0.94% on the day, with strong analyst support showing 85% buy ratings and a $111.20 consensus price target. The stock demonstrates solid revenue growth, reaching $402.07 billion in 2025, though net margins compressed to 1.18%. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 forecast. Technical indicators show a bearish trend with key support at $85.

CVS presents a compelling value opportunity with attractive valuation ratios (P/E 23.17, P/S 0.27) and consistent dividend payments. However, declining profit margins and ongoing regulatory scrutiny pose risks. The company's Medicare expansion and healthcare services growth provide upside potential, but investors should monitor reimbursement pressures and competitive dynamics in the evolving healthcare landscape.

Deutsche Bank AG

Deutsche Bank (DB) trades at $33.58, showing minimal daily movement (+0.09%). The stock presents mixed signals with bearish technical indicators but attractive valuation metrics including a P/E of 9.09 and P/B of 0.71. Recent earnings show volatility with a Q2 2026 miss but strong Q1 2026 beat. The company demonstrates improved financial health with 2025 net cash flow of $7.61B and rising revenue trends from $30.0B in 2024 to $32.1B in 2025.

DB offers value investment potential with below-market valuations and positive cash flow generation, though technical weakness and mixed analyst sentiment (21% buy, 58% hold) suggest cautious optimism. Key risks include investment banking revenue volatility and significant workforce retirement challenges. The path to 2028 targets depends on wealth management growth and cost control execution.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

CVS

No sentiment data available yet.

DB
100% Buy0% Sell
Avg holding period · 80 Days

Top news

Latest headlines on both assets

About CVS Health Corp

Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.

Read more on CVS →

About Deutsche Bank AG

In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.

Read more on DB →